Efficacy and direct costs of chronic hepatitis C treatment with first generation NS3/4A protease inhibitors in a real life population

INTRODUCTION: Recent years have brought a significant advance in chronic hepatitis C (CHC) treatment that includes development of direct acting antivirals (DAA). Two of them, boceprevir (BOC) and telaprevir (TVR), were first approved for treatment of patients infected with CHC genotype 1 in combinat...

Descripción completa

Detalles Bibliográficos
Autores principales: Piekarska, Anna, Koślińska-Berkan, Ewa, Wójcik, Kamila, Skubała, Anna, Jabłkowski, Maciej, Deroń, Zbigniew, Berkan-Kawińska, Aleksandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2016
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497430/
https://www.ncbi.nlm.nih.gov/pubmed/28856277
http://dx.doi.org/10.5114/ceh.2016.63869

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497430/
https://www.ncbi.nlm.nih.gov/pubmed/28856277
http://dx.doi.org/10.5114/ceh.2016.63869

Ejemplares similares